A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00637273
First received: March 6, 2008
Last updated: June 4, 2014
Last verified: June 2014
  Purpose

This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will also be compared.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: exenatide once weekly
Drug: sitagliptin
Drug: pioglitazone
Drug: placebo tablet
Drug: placebo once weekly
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change in HbA1c From Baseline to Week 26 [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Absolute change in HbA1c from baseline (Day 1) to Week 26 [Week 26 - Baseline].


Secondary Outcome Measures:
  • Percentage of Subjects Achieving HbA1c Target of <7% at Week 26 [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
    Percentages of subjects achieving HbA1c target values of <7% at Week 26.

  • Percentage of Subjects Achieving HbA1c Target of <=6.5% at Week 26 [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
    Percentages of subjects achieving HbA1c target values of <=6.5% at Week 26.

  • Percentage of Subjects Achieving HbA1c Target of <=6.0% at Week 26 [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
    Percentages of subjects achieving HbA1c target values of <=6.0% at Week 26.

  • Change in Body Weight From Baseline to Week 26 [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Change in body weight from baseline (Day 1) to Week 26.

  • Change in Fasting Plasma Glucose From Baseline to Week 26 [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Change in fasting plasma glucose from baseline (Day 1) to Week 26.

  • Change in Systolic Blood Pressure From Baseline to Week 26 [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Change in systolic blood pressure from baseline (Day 1) to Week 26.

  • Change in Diastolic Blood Pressure From Baseline to Week 26 [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Change in diastolic blood pressure from baseline (Day 1) to Week 26.

  • Change in Fasting Total Cholesterol From Baseline to Week 26 [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Change in fasting total cholesterol from baseline (Day 1) to Week 26.

  • Change in Fasting High-density Lipoprotein (HDL) From Baseline to Week 26 [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Change in fasting HDL from baseline (Day 1) to Week 26.

  • Ratio of Fasting Triglycerides at Week 26 to Baseline [ Time Frame: Day 1, Week 26 ] [ Designated as safety issue: No ]
    Ratio of triglycerides (measured in mg/dL) at Week 26 to baseline (Day 1). Log (Postbaseline Triglycerides) - log (Baseline Triglycerides); change from baseline to endpoint is presented as ratio of endpoint to baseline.

  • Assessment on Event Rate of Treatment-emergent Hypoglycemic Events [ Time Frame: Day 1 to Week 26 ] [ Designated as safety issue: Yes ]
    Major hypoglycemia: events that, in the judgment of the investigator or physician, resulted in loss of consciousness, seizure, coma, or other change in mental status consistent with neuroglycopenia, in which symptoms resolved after administration of intramuscular glucagon or intravenous glucose, required third-party assistance, and was accompanied by a blood glucose concentration < 54 mg/dL prior to treatment. Minor hypoglycemia: symptoms consistent with hypoglycemia and blood glucose concentration < 54 mg/dL prior to treatment and not classified as major hypoglycemia.


Enrollment: 514
Study Start Date: January 2008
Study Completion Date: July 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: exenatide once weekly
subcutaneous injection, 2.0mg, once a week
Drug: placebo tablet
oral tablet, once a day
Active Comparator: 2 Drug: sitagliptin
oral tablet, 100mg, once a day
Other Name: Januvia
Drug: placebo once weekly
subcutaneous injection, once a week
Active Comparator: 3 Drug: pioglitazone
oral tablet, 45mg, once a day
Drug: placebo once weekly
subcutaneous injection, once a week

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has been diagnosed with type 2 diabetes mellitus
  • Has a hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at study start
  • Has a body mass index (BMI)of 25 kg/m2 to 45 kg/m2, inclusive, at study start
  • Has been on a stable treatment regimen of metformin for a minimum of 2 months prior to study start
  • Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start:

    1. Hormone replacement therapy (female subjects)
    2. Oral contraceptives (female subjects)
    3. Antihypertensive agents
    4. Lipid-lowering agents
    5. Thyroid replacement therapy
    6. Antidepressant agents
    7. Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL®], sibutramine [MERIDIA®], topiramate [TOPAMAX®]) and over-the-counter antiobesity agents

Exclusion Criteria:

  • Has been previously exposed to exenatide once weekly
  • Has donated blood within 60 days of study start or is planning to donate blood during the study
  • Currently being treated, or is expected to require or undergo treatment with any of the following treatment-excluded medications:

    1. Exenatide (BYETTA®) or any Dipeptidyl peptidase-4 DPP-4)inhibitor, sulfonylurea (SU), thiazolidinedione (TZD), or glucagon-like peptide (GLP)-1 analog within 3 months prior to study start
    2. Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of study start
    3. Insulin within 2 weeks of study start or for more than 1 week within 3 months of study start
    4. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption
    5. Drugs interacting with the CYP2C8 enzyme system, including gemfibrozil (LOPID®) and rifampin
  • Has received any investigational drug within 1 month (or five half-lives of investigational drug, whichever is greater) of study start
  • Has previously experienced a clinically significant adverse event (e.g., significant edema) related to TZD or DPP-4 inhibitor use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00637273

  Hide Study Locations
Locations
United States, Arizona
Research Site
Peoria, Arizona, United States
United States, California
Research Site
Artesia, California, United States
Research Site
Concord, California, United States
Research Site
Encino, California, United States
Research Site
Greenbrae, California, United States
Research Site
La Mesa, California, United States
Research Site
Orange, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Whittier, California, United States
United States, Colorado
Research Site
Colorado Springs, Colorado, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Coral Gables, Florida, United States
Research Site
Deland, Florida, United States
Research Site
Melbourne, Florida, United States
Research Site
Miami, Florida, United States
Research Site
New Port Richey, Florida, United States
United States, Georgia
Research Site
Decatur, Georgia, United States
United States, Indiana
Research Site
Avon, Indiana, United States
United States, Kansas
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Paducah, Kentucky, United States
United States, Louisiana
Research Site
Baton Rouge, Louisiana, United States
Research Site
New Orleans, Louisiana, United States
United States, Maryland
Research Site
Oxon Hill, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, Michigan
Research Site
Chelsea, Michigan, United States
Research Site
Ypsilanti, Michigan, United States
United States, Minnesota
Research Site
St. Louis Park, Minnesota, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
United States, Montana
Research Site
Butte, Montana, United States
United States, Nebraska
Research Site
Lincoln, Nebraska, United States
United States, Nevada
Research Site
Las Vegas, Nevada, United States
United States, New York
Research Site
New Hyde Park, New York, United States
Research Site
New Windsor, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
United States, North Carolina
Research Site
Durham, North Carolina, United States
Research Site
Statesville, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
United States, Ohio
Research Site
Athens, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Dayton, Ohio, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
United States, South Dakota
Research Site
Rapid City, South Dakota, United States
United States, Tennessee
Research Site
Memphis, Tennessee, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
San Antonio, Texas, United States
United States, Virginia
Research Site
Richmond, Virginia, United States
United States, Washington
Research Site
Olympia, Washington, United States
Research Site
Spokane, Washington, United States
Research Site
Tacoma, Washington, United States
India
Research Site
Bangalore, India
Research Site
Indore, India
Research Site
Karnal, India
Research Site
Mumbai, India
Research Site
Pune, India
Mexico
Research Site
Mexico City, Distrito Federal, Mexico
Research Site
Guadalajara, Jalisco, Mexico
Research Site
Zapopan, Jalisco, Mexico
Research Site
Cuernavaca, Morelos, Mexico
Research Site
Monterrey, NuevoLeon, Mexico
Research Site
Toluca, Mexico
Sponsors and Collaborators
AstraZeneca
Eli Lilly and Company
Investigators
Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00637273     History of Changes
Other Study ID Numbers: BCB106 (DURATION - 2)
Study First Received: March 6, 2008
Results First Received: February 14, 2012
Last Updated: June 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
diabetes
exenatide once weekly
Byetta
sitagliptin
Januvia
thiazolidinedione
Amylin
Lilly
Pioglitazone

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Exenatide
Pioglitazone
Sitagliptin
2,4-thiazolidinedione
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 19, 2014